Skip to content

Validation of BodPod in Pediatric Anorexia Nervosa

Accuracy of Air Displacement Plethysmography Compare to Dual X-ray Absorptiometry (DXA) in Girls With Anorexia Nervosa

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04321317
Acronym
PADAAM
Enrollment
10
Registered
2020-03-25
Start date
2021-04-19
Completion date
2023-03-01
Last updated
2025-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anorexia Nervosa

Brief summary

Anorexia nervosa is a severe cause of undernutrition. It leads to a dramatic decrease of weight with an important modification of the body composition. During the renutrition phase, disharmonious body composition recovery is a relapse factor. Dual X-ray absorptiometry (DXA) is the gold standard to study body composition in children with anorexia nervosa. But, due to technical limits, DXA analysis needs to take in account a potential failure to thrive with an adjustment on height. Moreover DXA needs an irradiation which does not allow close repeat measurements. Since several years, a simple, non-invasive, non-irradiant method for measure of body composition has been developed in pediatrics: the air displacement plethysmography (ADP). Actually, only one device is available for this measurement: the BodPod®. However, feasibility and accuracy of ADP compare to DXA have not been evaluated in pediatric anorexia nervosa. The aim of this study is to compare the accuracy of BodPod® compare to DXA in girls with anorexia nervosa.

Interventions

OTHERMeasure of body composition by Air Displacement Plethysmography (ADP)

Each patient included will have one measure of body composition by Air Displacement Plethysmography (ADP) during the initial consultation in the referent center for food disorders of Lyon and one year later.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
8 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Female patients aged between 8 and 18 years * Female with a diagnosis of anorexia nervosa according to the DSM V classification, restrictive type or hyperphagic / purgative access type, evolving for less than 3 years. * Female who received explanations adapted to their level of understanding for this study * Female who expressed their consent to participate to this study * Female whose parents or holders of parental authority have been informed and signed free and informed consent * Female affiliated to a social security scheme

Exclusion criteria

* Patients with psychotic symptoms * Patients with claustrophobia * Patients with severe respiratory disease

Design outcomes

Primary

MeasureTime frameDescription
Accuracy of Air Displacement Plethysmography (ADP) for body fat mass measurement1 yearThe accuracy of Air Displacement Plethysmography (ADP) will be compare to Dual X-ray Absorptiometry (DXA) according to the percentage of body fat mass measurement. The hypothesis will be validating if difference in percentage in body fat mass between ADP and DXA is below the 4%. The measurement will be done two times at 1 year interval

Secondary

MeasureTime frameDescription
Acceptability of Air Displacement Plethysmography (ADP) by the patient compared to Dual X-ray Absorptiometry (DXA)1 yearThe questionnaire includes 3 questions after the ADP using simple analog visual scales adapted to children comprehension. The measurement will be done two times at 1 year interval
Accuracy of Air Displacement Plethysmography (ADP) compare to Bio Electrical Impedance (BEI)1 yearThe difference between percentage of body fat mass will quantified between ADP and BEI. The measurement will be done two times at 1 year interval
Longitudinal evolution of the percentage of body fat mass1 yearThe evolution of the percentage of body fat mass will be evaluated after 1 year of evolution.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026